Detailed Product Description
Procaine Penicillin powder for injection
INDICATIONS AND USAGE
Penicillin G procaine is indicated in the treatment of
moderately severe infections in both adults and pediatric patients
due to penicillin-G-susceptible microorganisms that are susceptible
to the low and persistent serum levels common to this particular
dosage form in the indications listed below. Therapy should be
guided by bacteriological studies (including susceptibility tests)
and by clinical response.
NOTE: When high, sustained serum levels are required, aqueous
penicillin G, either IM or IV, should be used.
The following infections will usually respond to adequate
dosages of intramuscular penicillin G procaine: Moderately severe
to severe infections of the upper respiratory tract, skin and
soft-tissue infections, scarlet fever, and erysipelas due to
susceptible streptococci (Group A-without bacteremia).
NOTE: Streptococci in Groups A, C, G, H, L, and M are very
sensitive to penicillin G. Other groups, including Group D
(enterococcus), are resistant. Aqueous penicillin is recommended
for streptococcal infections with bacteremia.
Moderately severe infections of the respiratory tract due to
susceptible pneumococci.
NOTE: Severe pneumonia, empyema, bacteremia, pericarditis,
meningitis, peritonitis, and arthritis of pneumococcal etiology are
better treated with aqueous penicillin G during the acute
stage.
Moderately severe infections of the skin and soft tissues due to
susceptible staphylococci (penicillin G-susceptible).
NOTE: Reports indicate an increasing number of strains of
staphylococci resistant to penicillin G, emphasizing the need for
culture and sensitivity studies in treating suspected
staphylococcal infections. Indicated surgical procedures should be
performed.
Fusospirochetosis (Vincent's gingivitis and pharyngitis).
Moderately severe infections of the oropharynx due to susceptible
fusiform bacilli and spirochetes.
NOTE: Necessary dental care should be accomplished in infections
involving the gum tissue.
Syphilis (all stages) due to susceptible Treponema pallidum.
NOTE: This drug should not be used in the treatment of
beta-lactamase producing organisms which include most strains of
Neisseria gonorrhea.
Yaws, Bejel, Pinta due to susceptible organisms.
Penicillin G procaine is an adjunct to antitoxin for prevention
of the carrier stage of diphtheria due to susceptible C.
diphtheriae.
Anthrax due to Bacillus anthracis, including inhalational
anthrax (post-exposure): to reduce the incidence or progression of
the disease following exposure to aerosolized Bacillus
anthracis.
Rat-bite fever due to susceptible Streptobacillus moniliformis
and Spirillum minus organisms.
Erysipeloid due to susceptible Erysipelothrix rhusiopathiae.
Subacute bacterial endocarditis, only in extremely sensitive
infections, due to susceptible Group A streptococci
CONTRAINDICATIONS
A previous hypersensitivity reaction to any penicillin is a
contraindication.
DOSAGE AND ADMINISTRATION
Penicillin G procaine (aqueous) is for intramuscular injection
only.
Pneumonia (pneumococcal), moderately severe (uncomplicated):
600,000 to 1,000,000 units daily.
Streptococcal infections (Group A), moderately severe to severe
tonsillitis, erysipelas, scarlet fever, upper respiratory tract,
skin and soft tissue: 600,000 to 1,000,000 units daily for 10-day
minimum.
Staphylococcal infections, moderately severe to severe: 600,000
to 1,000,000 units daily.
In pneumonia, streptococcal (Group A) and staphylococcal
infections in pediatric patients under 60 pounds: 300,000 units
daily.
Bacterial endocarditis (Group A streptococci) only in extremely
sensitive infections: 600,000 to 1,000,000 units daily.
Penicillin G procaine is not recommended for prophylaxis against
bacterial endocarditis. For prophylaxis against bacterial
endocarditis in patients with congenital heart disease or rheumatic
or other acquired valvular heart disease when undergoing dental
procedures or surgical procedures of the upper respiratory tract,
use penicillin V. For patients unable to take oral medications,
aqueous penicillin G is recommended.
Syphilis
Primary, secondary, and latent with a negative spinal fluid in
adults and pediatric patients over 12 years of age: 600,000 units
daily for 8 days-total 4,800,000 units.
Late (tertiary, neurosyphilis, and latent syphilis with positive
spinal-fluid examination or no spinal-fluid examination): 600,000
units daily for 10 to 15 days-total 6 to 9 million units.
Congenital syphilis under 70-lb. body weight: 50,000
units/kg/day for 10 days.
Yaws, Bejel, and Pinta: Treatment as for syphilis in
corresponding stage of disease.
Diphtheria-adjunctive therapy with antitoxin: 300,000 to 600,000
units daily.
Diphtheria carrier state: 300,000 units daily for 10 days.
Anthrax-cutaneous: 600,000 to 1,000,000 units/day.
Anthrax-inhalational (post-exposure): 1,200,000 units every 12
hours in adults, 25,000 units per kilogram of body weight (maximum
1,200,000 unit) every 12 hours in children. The available safety
data for penicillin G procaine at this dose would best support a
duration of therapy of 2 weeks or less. Treatment for inhalational
anthrax (post-exposure) must be continued for a total of 60 days.
Physicians must consider the risks and benefits of continuing
administration of penicillin G procaine for more than 2 weeks or
switching to an effective alternative treatment.
Vincent's infection (fusospirochetosis): 600,000 to 1,000,000
units/day.
Erysipeloid: 600,000 to 1,000,000 units/day.
Streptobacillus moniliformis and Spirillum minus (rat-bite
fever): 600,000 to 1,000,000 units/day.
ADVERSE REACTIONS Allergic Reactions
Penicillin is a substance of low toxicity but does possess a
significant index of sensitization. The following hypersensitivity
reactions associated with use of penicillin have been reported:
Skin rashes, ranging from maculopapular eruptions to exfoliative
dermatitis; urticaria; serum-sicknesslike reactions, including
chills, fever, edema, arthralgia, and prostration. Severe and often
fatal anaphylaxis has been reported. As with other treatments for
syphilis, the Jarisch-Herxheimer reaction has been reported.
Procaine toxicity manifestations and hypersensitivity reactions
have been reported
Gastrointestinal
Pseudomembranous colitis has been reported with the use of
penicillin G. Onset of pseudomembranous colitis symptoms may occur
during or after antibiotic treatment
|